Table 3.
Time to onset of four immune checkpoint inhibitors-related hypophysitis.
| Immune checkpoint inhibitors | Distribution of time between initiation of ICI and onset of hypophysitis [case (%)] | Median time to occur [d, M (Q1, Q3)] | ||||||
|---|---|---|---|---|---|---|---|---|
| ≤30 d | 31–90 d | 91–180 d | 181–270 d | 271–360 d | 361–720 d | 721–1800 d | ||
| Nivolumab | 89 (28.62) | 101 (32.48) | 66 (21.22) | 25 (8.04) | 14 (4.50) | 12 (3.86) | 4 (1.29) | 63 (21, 130.5) |
| Pembrolizumab | 23 (31.94) | 16 (22.22) | 17 (23.61) | 7 (9.72) | 6 (8.33) | 2 (2.78) | 1 (1.39) | 84.5 (19.25, 169.75) |
| Ipilimumab | 82 (27.61) | 171 (57.58) | 32 (10.77) | 5 (1.68) | 2 (0.67) | 2 (0.67) | 3 (1.01) | 50 (24, 70) |
| Atezolizumab | 2 (11.11) | 3 (16.67) | 5 (27.78) | 6 (33.33) | 0 (0) | 1 (5.56) | 1 (5.56) | 141.5 (91.25, 230.75) |
The data in the table were obtained from the US FAERS database for the period from the first quarter of 2004 to the second quarter of 2021; the shortest time between the start nivolumab drug use and the onset of hypophysitis was 1 d and the longest time was 1196 d.